The Procter Gamble Company

The Cleveland Clinic Foundation

David Thomas Stanton

Johan Smets

Lynette Anne Makins Holland

Jonathan Richard Stonehouse

Oreste Todini

Toan Trinh

Zaiyou Liu

Eva Schneiderman

Stephen Robert Schofield

Jeffrey John Scheibel

Stanley Leon Hazen

Susana Fernandez Prieto

Helen Bernardo Tordil

John August Wos

Mary Vijayarani Barnabas

Joseph H Gardner

Jose Carlos Garcia-Garcia

Eugene Paul Gosselink

Phillip Kyle Vinson

James Berger Camden

Gayle Marie Frankenbach

Frank Hulskotter

Patrick Firmin August Delplancke

Scott Leroy Cron

Hugo Robert Germain Denutte

John William Smith

Philip Kraft

An Pintens

Jerzy A Bajgrowicz

Ryan Michael West

George Kavin Morgan, Iii

Thierry Granier

Allan Campbell McRitchie

Freek Annie Camiel Vrielynck

Randall Thomas Reilman

William Eoghan Staite

Fabienne Pastor

Christelle Marie Sandrine Bonnet

Jose Maria Velazquez Mendoza

Michael Lee Kramer

Sarah Kyakyo Kanyunyuzi Nyakana

Michael Reilly

Thomas Alfred Inglin

Angela Jane Deutsch

George Franklin Gerberick

Isabelle Guimet

David Blair Cody

Ronald David Turner

Rafael Trujillo Rosaldo

Koen Van Aken

William David Laidig

Neil Thomas Fairweather

Jamila Tajmamet

Andreas Hanhart

Lynette Anne Holland

Jodie Michelle Reed

Jodie Michele Reed

Bram Denolf

Prakash J Madhav

Inge Helena Hubert Laureyn

Susana Fernandez-Prieto

José Maria Velazquez Mendoza

Fabienne Nmn Pastor

Oreste Nmn Todini

Allan Campbell Mcritchie

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.

Methods for inhibiting conversion of carnitine to trimethylamine (TMA)

The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.

Methods for inhibiting conversion of choline to trimethylamine (TMA)

The present invention relates to a composition having improved or enhanced fidelilty and/or longevity of the fragrance profile, comprising from about 10 wt % to about 30 wt % of low volatile fragrance materials having a vapor pressure less than 0.001 Torr (0.000133 kPa) at 25&#xb0; C., wherein the wt % is relative to the total weight of the fragrance component, and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.

Fragrance compositions and uses thereof

The present invention relates to a composition having improved or enhanced fidelity and/or longevity of the fragrance profile, comprising fragrance materials in a diamond construction and at least one substantially non-odorous fragrance modulator. The invention also relates to methods of use of the compositions for perfuming suitable substrates, including hard surfaces and body parts, particularly skin and hair.

A perfume mixture comprising an olfactive index and vapor pressure distribution for improved diffusion from activated air fresheners and methods thereof are provided.

Perfume mixtures comprising an olfactive index for activated air fresheners

A fragrance composition having improved intensity and/or longevity of the fragrance profile, including less than about 30 wt % of low volatile fragrance materials (i.e., base notes) having a vapor pressure less than 0.001 Torr at 25&#xb0; C., and at least one non-odorous fragrance modulator form from an alkoxylated glucoside.

Fragrance compositions

The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

Perfume systems

The present application relates to perfume systems and consumer products comprising new perfumes and/or such perfume systems, as well as processes for making and using such perfume systems and consumer products.

The present invention relates to stable, aqueous fabric softening compositions, fabric softening methods and articles of manufacture that use such fabric softening compositions comprising preferred polyalkyleneoxy polysiloxanes selected from the group consisting of polyethyleneoxy polysiloxane, polyethyleneoxy/polypropyleneoxy polysiloxanes, and mixtures thereof. The composition is preferably applied as small particle size droplets, especially from spray containers. The present invention also relates to a method of identifying, selecting, and/or designing the preferred polyethyleneoxy polysiloxanes and/or polyethyleneoxy/polypropyleneoxy polysiloxanes that provide superior fabric softening performance in general, and especially for use in the fabric softening composition of the present invention.

Fabric softening compositions and methods

The present invention relates to a computational method for predicting a desired property and/or performance of polymers, and/or identifying and designing polymers that provide said desired property and/or performance, wherein the desired property can be provided by the neat, undiluted polymers, or diluted polymers in a composition. The method is a QSAR approach wherein the descriptors used are structural descriptors which are experimentally generated and/or derived from one or more analytical methods.

Predictive method for polymers

A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, is disclosed. This same composition is can be used to treat viral infections, particularly HIV. The composition comprises from about 10 mg to about 10000 mg of a carbamic acid ester derivative of the formula:

Viral treatment

A pharmaceutical composition is disclosed to treat viral infections, particularly HIV and hepatitis, as well as to treat fungal infections of the genus,or,. The composition comprises from about 10 mg to about 6000 mg of a 2-thienyl-imidazolo &lsqb;4,5&rsqb;pyridine of the formula:

Growing community of inventors

Hamilton, OH, United States of America

David Thomas Stanton